{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:23:28Z","timestamp":1787275408254,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway are established preventive treatments for migraine. Although treatment response is often summarized by reduction in monthly migraine days (MMD), patients and clinicians also judge benefit by changes in disability and headache impact. We examined how often frequency-based and patient-reported outcome measure (PROM) responder definitions classify the same individuals after CGRP-pathway monoclonal antibody treatment and characterized the direction of discordant response patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a secondary analysis of a public patient-level dataset including 417 patients treated with a first CGRP-pathway monoclonal antibody. Response was defined using source-study criteria: subtype-specific MMD response, Migraine Disability Assessment (MIDAS) response, and Headache Impact Test-6 (HIT-6) response. We quantified response rates, pairwise agreement, directional discordance, and continuous-change correlations. Exploratory logistic regression examined baseline features associated with discordant classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MMD, MIDAS, and HIT-6 response occurred in 227\/417 (54.4%), 243\/417 (58.3%), and 254\/417 (60.9%) patients, respectively. Only 131\/417 (31.4%) met all three response definitions, and 207\/417 (49.6%) had discordant classification across the three endpoints. Observed agreement between MMD and MIDAS response was 66.4% with kappa 0.32, and observed agreement between MMD and HIT-6 response was 68.6% with kappa 0.36. When MMD was compared with any PROM response, PROM-only response occurred in 111\/417 (26.6%) patients and frequency-only response in 18\/417 (4.3%). Correlations between continuous improvements in frequency-based and patient-reported outcomes were moderate rather than strong.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After CGRP-pathway monoclonal antibody treatment, responder classification depended on whether response was defined by migraine frequency, disability, or headache impact. PROM-only response was more frequent than frequency-only response, suggesting that some patients may report meaningful improvement in disability or impact even when they do not cross diary-based frequency thresholds. These findings do not establish a new responder definition or show that one endpoint is superior; they support complementary reporting of headache frequency and patient-reported burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05074-2","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:55:09Z","timestamp":1781495709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Responder discordance between migraine frequency and patient-reported outcomes after CGRP-pathway monoclonal antibody treatment: a secondary analysis of public patient-level data"],"prefix":"10.1186","volume":"26","author":[{"given":"Chuntao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"10283","key":"5074_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7.","journal-title":"Lancet"},{"issue":"4","key":"5074_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"issue":"1","key":"5074_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for migraine prevention\u2009\u2013\u20092022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"22","key":"5074_CR4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"issue":"6","key":"5074_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"issue":"9","key":"5074_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"issue":"24","key":"5074_CR7","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"issue":"1","key":"5074_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, Dahl\u00f6f C, D\u2019Amico D, Diener HC, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6\u201338. https:\/\/doi.org\/10.1177\/0333102411417901.","journal-title":"Cephalalgia"},{"issue":"10","key":"5074_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, International Headache Society Clinical Trials Committee, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026\u201344. https:\/\/doi.org\/10.1177\/0333102420941839.","journal-title":"Cephalalgia"},{"issue":"5","key":"5074_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, International Headache Society Clinical Trials Standing Committee, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815\u201332. https:\/\/doi.org\/10.1177\/0333102418758283.","journal-title":"Cephalalgia"},{"issue":"6 Suppl 1","key":"5074_CR11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20\u20138. https:\/\/doi.org\/10.1212\/WNL.56.suppl_1.S20.","journal-title":"Neurology"},{"issue":"8","key":"5074_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963\u201374. https:\/\/doi.org\/10.1023\/A:1026119331193.","journal-title":"Qual Life Res"},{"issue":"3","key":"5074_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357\u201367. https:\/\/doi.org\/10.1177\/0333102410379890.","journal-title":"Cephalalgia"},{"key":"5074_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12955-014-0117-0","volume":"12","author":"R Rendas-Baum","year":"2014","unstructured":"Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes. 2014;12:117. https:\/\/doi.org\/10.1186\/s12955-014-0117-0.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5074_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0333102413497599","volume":"34","author":"AFH Smelt","year":"2014","unstructured":"Smelt AFH, Assendelft WJJ, Terwee CB, Ferrari MD, Blom JW. What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia. 2014;34(1):29\u201336. https:\/\/doi.org\/10.1177\/0333102413497599.","journal-title":"Cephalalgia"},{"key":"5074_CR16","doi-asserted-by":"publisher","unstructured":"Ruscheweyh R, Forderreuther S, Freilinger T, Gaul C, Gossrau G, Jurgens TP, et al. Minimal important difference of the Migraine Disability Assessment (MIDAS): longitudinal data from the DMKG Headache Registry. Cephalalgia. 2024;44(7):3331024241261077. https:\/\/doi.org\/10.1177\/03331024241261077.","DOI":"10.1177\/03331024241261077"},{"key":"5074_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s40122-025-00784-w","volume":"14","author":"CH G\u00f6bel","year":"2025","unstructured":"G\u00f6bel CH, Heinze A, Heinze-Kuhn K, M\u00fcller U, Cirkel A, G\u00f6bel H. Evaluating treatment success in CGRP antibody prophylaxis: a retrospective cohort study comparing monthly migraine days, MIDAS scores, and HIT-6 scores. Pain Ther. 2025;14:1899\u2013914. https:\/\/doi.org\/10.1007\/s40122-025-00784-w.","journal-title":"Pain Ther"},{"key":"5074_CR18","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.15722864","author":"C G\u00f6bel","year":"2025","unstructured":"G\u00f6bel C. Evaluating treatment success in CGRP antibody prophylaxis: a retrospective cohort study comparing monthly migraine days, MIDAS scores, and HIT-6 scores [dataset]. Zenodo; 2025. https:\/\/doi.org\/10.5281\/zenodo.15722864.","journal-title":"Zenodo"},{"key":"5074_CR19","doi-asserted-by":"publisher","first-page":"e77146","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. eLife. 2022;11:e77146. https:\/\/doi.org\/10.7554\/eLife.77146.","journal-title":"eLife"},{"key":"5074_CR20","doi-asserted-by":"publisher","unstructured":"Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study [dataset]. Dryad Digital Repository; 2022. https:\/\/doi.org\/10.5061\/dryad.w3r2280t2.","DOI":"10.5061\/dryad.w3r2280t2"},{"issue":"20","key":"5074_CR21","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A. Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology. 2020;95(20):e2794\u2013802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740.","journal-title":"Neurology"},{"issue":"10","key":"5074_CR22","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","journal-title":"PLoS Med"},{"key":"5074_CR23","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"158","key":"5074_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209\u201312. https:\/\/doi.org\/10.1080\/01621459.1927.10502953.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"5074_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37\u201346. https:\/\/doi.org\/10.1177\/001316446002000104.","journal-title":"Educ Psychol Meas"},{"issue":"1","key":"5074_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-020-01192-5","volume":"21","author":"C Tiseo","year":"2020","unstructured":"Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. J Headache Pain. 2020;21(1):126. https:\/\/doi.org\/10.1186\/s10194-020-01192-5.","journal-title":"J Headache Pain"},{"issue":"4","key":"5074_CR27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40120-025-00785-z","volume":"14","author":"C Tana","year":"2025","unstructured":"Tana C, Onan D, Messina R, Waliszewska-Pros\u00f3\u0142 M, Garcia-Azorin D, Leal-Vega L, et al. From headache to heart health: investigating the migraine-cardiovascular disease connection. Neurol Ther. 2025;14(4):1229\u201368. https:\/\/doi.org\/10.1007\/s40120-025-00785-z.","journal-title":"Neurol Ther"},{"issue":"3","key":"5074_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1474-4422(25)00477-6","volume":"25","author":"D Martinelli","year":"2026","unstructured":"Martinelli D, De Icco R, Al-Khazali HM, Ashina S, Diener HC, Dodd-Glover F, et al. Advances in migraine prevention. Lancet Neurol. 2026;25(3):279\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(25)00477-6.","journal-title":"Lancet Neurol"},{"issue":"2","key":"5074_CR29","doi-asserted-by":"publisher","first-page":"333102425132060","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):3331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608.","journal-title":"Cephalalgia"},{"issue":"10","key":"5074_CR30","doi-asserted-by":"publisher","first-page":"333102425138772","DOI":"10.1177\/03331024251387721","volume":"45","author":"P Pozo-Rosich","year":"2025","unstructured":"Pozo-Rosich P, Caronna E, Sacco S, Peres MFP, Ashina S, \u00d6zge A, et al. Early treatment in migraine - A call to shift prevention from attacks to disease progression: a position statement from the International Headache Society. Cephalalgia. 2025;45(10):3331024251387721. https:\/\/doi.org\/10.1177\/03331024251387721.","journal-title":"Cephalalgia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05074-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:33:07Z","timestamp":1787272387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05074-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"532"}}